Featured Research

from universities, journals, and other organizations

Gene therapy to reverse heart failure ready for clinical trials; Therapeutic effectiveness and safety of 'next great thing in heart failure' demonstrated

Date:
July 21, 2011
Source:
Thomas Jefferson University
Summary:
A promising gene therapy developed to prevent and reverse congestive heart failure is on the verge of clinical trials, after years of proving itself highly effective in the lab and a large animal study.

A promising gene therapy developed, in part, at Thomas Jefferson University's Center for Translational Medicine to prevent and reverse congestive heart failure is on the verge of clinical trials, after years of proving itself highly effective in the lab and a large animal study.

Reporting in the online July 20 issue of Science Translational Medicine, cardiology researchers have demonstrated feasibility, the long-term therapeutic effectiveness and the safety of S100A1 gene therapy in a large animal model of heart failure under conditions approximating a clinical setting.

"This is the last step you have to take to finish a very long line of research," said Patrick Most, M.D., adjunct assistant professor of medicine at Thomas Jefferson University, and lead author of the study who now heads the Institute for Molecular and Translational Cardiology at the University of Heidelberg, Germany. "The reversal of cardiac dysfunction in this pre-clinical heart failure model in the pig by restoring S100A1 levels in practically the same setting as in a patient is remarkable and will pave the way for a clinical trial."

The therapy works by raising diminished levels of the protein S100A1, a calcium-sensing protein in the diseased heart muscle cell, to normal. Previous research suggests this will prevent against heart failure development, particularly in people who have had a heart attack.

According to Dr. Most, "the therapeutic profile of S100A1 is a unique one as it targets and reverses the underlying causes of heart failure: progressive deterioration of contractile performance, electrical instability and energy deprivation."

About six million people in the United States have heart failure, and it results in about 300,000 deaths each year.

Work on S100A1 started bench side 15 years ago with Dr. Most and Walter J Koch, Ph.D., now director of the Center for Translational Medicine in the Department of Medicine in Jefferson Medical College of Thomas Jefferson University, who, with his team, have moved the research closer to bedside ever since.

Five years ago, Jefferson researchers showed that increasing levels of the protein above normal helped protect mouse hearts from further damage after simulated heart attacks. The hearts worked better and had stronger contractile force.

"We have pursued a completely different path over the years," said Dr. Most. "We have set up a translational pipeline and don't stick to just one model system. We took it step by step, and did whatever was necessary to go to the next level. We realized early on that a mouse is not a man. You need to design target-tailored translational research strategies and work in human-relevant model systems to take molecular discoveries from bench to bedside.

"With such a translational roadmap at hand, we are in the unique position to accelerate future development of molecular therapies."

In their latest study in Science Translational Medicine, Drs. Koch and Most and their team of researchers used a pig model -- this type more closely resembles human physiology, function and anatomy -- to determine the effectiveness and safety of the S100A1 gene therapy. Researchers were also able to administer it with certified catheters and delivery routes, just as a human patient would receive it. "We've shown its effectiveness in the lab. It worked in mice and rats, then pigs and now it's ready for humans," Dr Most adds.

Heart failure was induced in the pigs, and at 14 weeks showed significantly decreased S100A1 levels. Treatment, however, with the gene therapy prevented and reversed development of heart failure by restoring the S100A1 protein levels or getting them above normal.

"This therapy gets to the core of the disease," said Dr. Koch, who received the "Outstanding Investigator Award" for 2011 by the International Society for Heart Research for his work in heart failure gene therapy. "They are not just beta blockers or ancillary drugs, which only block the damage. This therapy makes the heart beats stronger and overcomes the damage from previous heart attacks. It's the next great thing in heart failure."

This is the final set of preclinical data needed to apply for investigational new drug status with the U.S. Food and Drug Administration and advance to a phase I clinical trial.

Researchers say one of the next steps is to find industry or private partners to help fund the work, as well as recruit eligible patients to enroll in the clinical trial.

"With National of Institutes of Health money in jeopardy, this could be translated faster with funds from other sources," said Dr. Koch. "It could fund both ongoing research with other targets using our translational roadmap and to take this particular target for heart failure into humans."


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sven T. Pleger, Changguang Shan, Jan Ksienzyk, Raffi Bekeredjian, Peter Boekstegers, Rabea Hinkel, Stefanie Schinkel, Barbara Leuchs, Jochen Ludwig, Gang Qiu, Christophe Weber, Philip Raake, Walter J. Koch, Hugo A. Katus, Oliver J. Mόller, Patrick Most. Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model. Science Translational Medicine, 2011; 3 (92): 92ra64 DOI: 10.1126/scitranslmed.3002097

Cite This Page:

Thomas Jefferson University. "Gene therapy to reverse heart failure ready for clinical trials; Therapeutic effectiveness and safety of 'next great thing in heart failure' demonstrated." ScienceDaily. ScienceDaily, 21 July 2011. <www.sciencedaily.com/releases/2011/07/110720142116.htm>.
Thomas Jefferson University. (2011, July 21). Gene therapy to reverse heart failure ready for clinical trials; Therapeutic effectiveness and safety of 'next great thing in heart failure' demonstrated. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2011/07/110720142116.htm
Thomas Jefferson University. "Gene therapy to reverse heart failure ready for clinical trials; Therapeutic effectiveness and safety of 'next great thing in heart failure' demonstrated." ScienceDaily. www.sciencedaily.com/releases/2011/07/110720142116.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) — In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) — A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) — The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) — President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins